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Abstract
Background: Assistance Publique-Hôpitaux de Paris (APHP), the largest public health care institution in France (38
hospitals, 23,000 beds, serving 11.6 millions inhabitants) launched in 1993 a long term programme to control and
survey multidrug resistant bacteria (MDR).
Findings: AP-HP MDR programme consisted in successive waves of actions: bundle measures to survey and
control cross transmission of MRSA and extended-spectrum betalactamase producing enterobacteria (ESBL) in 1993,
large campaign to promote the use of alcohol-based hand rub solution (ABHRS) in 2001, specific strategy to
quickly control the spread of emerging MDR (vancomycin resistant Enterococcus, VRE; carbapenemase producing
enterobacteria, CPE) in 2006, large campaign to decrease antibiotics consumption in 2006.
Following this programme, the ABHRS consumption dramatically increased, the antibiotic consumption decreased
by 10%, the incidence of MRSA, including MRSA bacteraemia, decreased by 2/3, all VRE and CPE events were
rapidly controlled. However, the incidence of ESBL, mainly Klebsiella pneumoniae and Escherichia coli, that remained
low and stable until 2003 increased markedly afterwards, justifying adapting our programme in the future.
Conclusion: A sustained and coordinated strategy can lead to control multidrug resistant bacteria at the level of a
large multihospital institution.
Keywords: antibiotic resistance control, carbapenemase producing enterobacteria, CPE, vancomycin resistant enter-
ococci, VRE, MRSA, quality programme, healthcare associated infections, HAI
Background
Multidrug resistance bacteria (MDR) jeopardizes the
quality of care by (a) complicating the treatment of
healthcare associated infections (HAI) and (b) increasing
the incidence of HAIs (e.g. in the case of methicillin
resistant Staphylococcus aureus, MRSA). Emergence of
vancomycin-resistant enterococci (VRE) and carbapene-
mase-producing enterobacteria (CPE) is nowadays a
major public health concern worldwide [1]. In 1993
Assistance Publique-Hôpitaux de Paris (AP-HP), the
largest public health care institution in France, launched
a long term programme to survey and control MDR.
Materials and methods
Setting
AP-HP is a public health institution administering 38
teaching hospitals (23 acute care and 15 rehabilitation/
long-term care hospitals, spread over Paris, suburbs and
surrounding counties), totalizing 23,000 beds (10% of all
public hospital beds in France) and serving 11.6 millions
of inhabitants. AP-HP admits approximately 1 million
inpatients per year, employs 19,000 physicians, 18,500
nurses and 29,800 assistant nurses. Local administrators
and medical committees manage AP-HP hospitals, but
decisions on large investments and medical
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developments are taken by the central administration. A
local infection control team (ICT) is in charge of pre-
vention and surveillance of HAI in each hospital but
actions of foremost importance for the whole institution,
e.g. MDR control programme, are coordinated centrally
by a multidisciplinary infection control team (infectious
disease physician, bacteriologist, epidemiologist and
nurse)[2].
MDR control programme
In 1993, AP-HP launched a long-term programme to
survey and control MDR. Each step of the programme
was implemented gradually in every AP-HP hospitals
and supported by a strong commitment of AP-HP cen-
tral and local administration. This implementation was
included as incentive in evaluation process within the
institution (quality indicator).
The 1st step (1993) was bundle measures to control
cross transmission of MRSA, whose incidence was at
that time higher in France than in other European coun-
tries, and extended-spectrum ß-lactamase producing
enterobacteria (ESBL): identification of MDR carriers by
passive and active surveillance, barrier precautions,
training and feedback [2].
The 2nd step was a large campaign (2001-2002) pro-
moting the use of alcohol-based hand rub solution
(ABHRS). This campaign provided pedagogical material
to the local ICT (ready to use slide sets, 200,000 bro-
chures, 14,000 posters). Importantly, AP-HP’s General
Director urged all administrators, head of departments
and chief nurses to support the implementation of the
campaign.
The 3rd step (2006) was a specific strategy to quickly
control the spread of emerging MDR (vancomycin resis-
tant enterococci, VRE; carbapenemase producing enter-
obacteria, CPE). Indeed, from August 2004 to December
2005, the monthly number of VRE cases increased sig-
nificantly [3] and the 1st outbreak of CPE [4] occurred
in AP-HP hospitals. In response to this worrying situa-
tion, an institutional “emerging MDR programme” was
designed: (a) quickly reporting every new VRE/CPE case
(defined as infected or colonized patient) to the AP-HP
central infection control team (CICT), (b) stopping
transfers to other units of the hospital or to other hospi-
tals of the cases and of the contact patients, defined as
any patient hospitalized in the same unit during the
same period of time as a VRE/CPE case, (c) screening
contact patients for VRE/CPE carriage (rectal swabbing)
extended to those already transferred from the involved
unit, and maintained this screening until the outbreak
was controlled, i.e. after all VRE/CPE patients have been
discharged and after a period of at least three months
without new case, (d) identifying discharged VRE/CPE
cases and contact patients when readmitted and (e)
cohorting patients in 3 distinct areas with dedicated
nursing staffs: “VRE/CPE case patients” section, “Con-
tact patients” section, “VRE/CPE-free patients” section
for newly admitted patients with no previous contact
with the case patients [4]. To stimulate the efforts made
by the local infection control teams and administrators,
the CICT (a) followed the number of new VRE/CPE
cases, and difficulties in programme implementation, (b)
visited regularly the hospitals to help the local teams in
applying the programme and (c) regularly disseminated
results within hospitals and central administration.
In 2008, based on the analysis of the 1st VRE/CPE
events [5], ICTs were advised to screen every patient
transferred from a foreign hospital for VRE/CPE.
Finally, a 4 years lasting campaign was launched in
2006 to decrease antibiotics consumption and, conse-
quently, the selection pressure on MDR: (a) identifying a
physician in each hospital as “antibiotic referent” in
charge of implementing antibiotic policy, (b) providing
teaching material to these referents (slide sets, 40,000
brochures, 15,000 posters), (c) stimulation by the Gen-
eral Director (see above). This campaign was based on
10 teasing messages: treat only bacterial infections,
know when to say “no” to antibiotics, know when to
stop antibiotics, treat only infection and no colonization,
use antibiotics wisely, know to say “no” to antibiotic
associations, re-evaluate antibiotic prescription after 2
days, prevent infections, limit invasive devices, prevent
cross transmission.
Results
The main results obtained in AP-HP through the pro-
gramme were as follows:
(a) Global ABHRS consumption increased from 2 to
30 litres per 1,000 hospital days (HD) between 2001 and
2010,
(b) Global antibiotic consumption decreased from 573
to 515 defined daily doses/1,000 HD between 2005 and
2010,
(c) All VRE and CPE events were rapidly controlled.
Indeed, after implementation of the specific measures in
2006, a progressive and significant decrease in the num-
ber of VRE cases was observed in AP-HP, contrasting
with the continuous increase that prevailed in 2004-05,
when only guidelines aiming at controlling cross trans-
mission of endemic multidrug resistant bacteria such as
MRSA were used (Figure 1).
The follow up of CPE shows that 63 events (1 event =
1 index case with or without secondary cases) occurred
between 2004 and 2011, resulting in 107 cases of infec-
tions or colonisations. Fifty-three of the events did not
lead to secondary cases whereas the ten others led to
outbreaks, totalizing 44 secondary cases (1-12 cases per
outbreak) [6]. The mean number of cases identified by
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CPE event, including the index case, decreased from 4.5
to 1.5 between 2004 and 2011, emphasizing efficacy of
the specific control measures [4,6]. Among the 63
events, 88% involved patients transferred from foreign
hospitals. Klebsiella pneumoniae was isolated in 43
events (including 8 outbreaks), Escherichia coli in 18
events (including 2 outbreaks), Enterobacter cloacae in 3
events, Citrobacter freundii and Enterobacter aerogenes
in 1 event each. Two species of enterobacteria were iso-
lated in 3 episodes. The carbapenemases involved in the
63 events were OXA-48 (51%), KPC (35%), VIM (6%),
NDM-1 (8%).
(d) The incidence of MRSA, including MRSA bacter-
aemia, decreased by 2/3 between 1993 and 2010 (Figure
2) [2],
(e) Finally, in contrast to the evolution of the MRSA inci-
dence seen above, the ESBL incidence, involving mainly K.
pneumoniae and E. coli, was contained at low rates (around
0.15 case per 1,000 HD) between 1993 and 2003, but mark-
edly increased afterwards up to 0.73 per 1,000 HD (Figure
2). The proportions of K. pneumoniae and E. coli were 10%
and 60% in 1996 and 50% and 20% in 2010, respectively.
This increase of ESBL incidence justifies to adapt our pro-
gramme, particularly concerning antibiotic policy, hand
hygiene and excreta management policy.
Conclusion
The AP-HP experience shows that a multifaceted, sus-
tained and coordinated strategy can lead to control


















































































































































































Predicted values from the segmented regression model
Predicted values (with 95% CI) from the segmented regression model estimated on period 1
Period 1 





Figure 1 Observed cases and predicted values (from segmented regression model) of monthly vancomycin-resistant Enterococcus
(VRE) epidemic cases (infections and colonizations) in the Assistance Publique-Hôpitaux de Paris before (period 1) and after
implementation of the institutional VRE infection control programme (periods 2 and 3). In period 1, measures to control cross
transmission of endemic MDR such as MRSA were applied, in period 2, a specific strategy to control the spread of emerging MDR was instituted.






























Figure 2 Change in the incidence per 1,000 hospital days (HD)
of methicillin-resistant Staphylococcus aureus (MRSA) and
extended-spectrum ß-lactamase producing enterobacteria
(ESBL) in acute care hospitals.
Fournier et al. Antimicrobial Resistance and Infection Control 2012, 1:9
http://www.aricjournal.com/content/1/1/9
Page 3 of 4
the level of a large regional multihospital institution.
Efforts should be maintained to continue to decrease
MRSA rates and to contain emergence of CPE and VRE
and reinforced to stop the progression of ESBL.
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